Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype
May 18th 2023Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.
Exemestane at 25 mg Noninferior in Reducing Serum Estradiol in Breast Cancer
April 24th 2023Investigators cite the need for further study of the 25 mg, 3 times weekly exemestane dosing schedule in prevention studies among those with post-menopausal, stage 0 to II estrogen receptor–positive breast cancer who can’t tolerate daily adjuvant treatment.
Enfortumab Vedotin Combo Gets Accelerated FDA Nod for Urothelial Cancer
April 3rd 2023Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.
FDA Gives Full Approval to Pembrolizumab in dMMR/MSI-H Solid Tumors
March 29th 2023Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, the FDA has given full approval to pembrolizumab for patients with microsatellite instability-high or mismatch repair deficient solid tumors.
BXCL701/Pembrolizumab Yields Durable Responses in Prostate Cancer Subtype
March 10th 2023All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCL
March 10th 2023Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From Chemo
March 6th 2023A prefilled autoinjector presentation of pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.
TFS Improves With Nivolumab, Salvage Nivolumab in Advanced Renal Cell Carcinoma
February 21st 2023Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.
Ponatinib Combo Demonstrates Superiority Vs Imatinib in Ph+ Leukemia Subtype
February 16th 2023An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.